Zhang Yongchang, Huang Zhe, Zeng Liang, Zhang Xiangyu, Li Yizhi, Xu Qinqin, Yang Haiyan, Lizaso Analyn, Xu Chunwei, Liu Jun, Wang Wenxian, Song Zhengbo, Ou Sai-Hong Ignatius, Yang Nong
Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
NPJ Precis Oncol. 2022 Mar 31;6(1):20. doi: 10.1038/s41698-022-00264-w.
This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.
这项回顾性研究调查了49例接受一线克唑替尼治疗的ROS1重排晚期非小细胞肺癌患者的疾病进展模式与获得性耐药分子机制之间的关联。我们发现，治疗中出现的ROS1点突变是克唑替尼耐药的主要分子机制，尤其是对于仅发生颅外疾病进展的患者。我们的研究结果突出了再次活检和基因检测对后续治疗管理的重要性。
